| Bioactivity | Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease[1]. |
| In Vivo | Yonkenafil (Tunodafil) hydrochloride (4-32 mg/kg, i.v. daily for 7 days) 能够改善中风后的行为结果并减少脑梗塞体积，抑制神经元凋亡，并通过调节 BDNF/TrkB 和 NGF/TrkA 的表达显着增强缺血脑中的突触功能[1]。 Animal Model: |
| Name | Yonkenafil hydrochloride |
| CAS | 804519-64-0 |
| Formula | C24H34ClN5O4S |
| Molar Mass | 524.08 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xuemei Chen, et al. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp Neurol. 2014 Nov;261:267-77. |
Yonkenafil hydrochloride
CAS: 804519-64-0 F: C24H34ClN5O4S W: 524.08
Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.